SenzaGen signs distribution agreement with the French test laboratory Eurosafe
Lund, July 16, 2018. SenzaGen (Nasdaq First North: SENZA) and the French CRO Eurosafe announce today that they have entered into a distribution agreement regarding GARDskin™ and GARDpotency™. The GARD™ portfolio consists of animal-free tests developed by SenzaGen for safety assessment of chemical ingredients and mixtures. The agreement confirms the interest in SenzaGen’s technology and opens up new business opportunities on the important French market. Under the agreement, Eurosafe will market and sell GARDskin™ and GARDpotency™ to its clients.
Eurosafe is a highly specialised contract research organization (CRO) with expertise in toxicology and regulatory services, and strives to present the best performing tests to its customers. Eurosafe carries out in vitro tests with focus on the cosmetics and pharmaceutical industries. According to the agreement, Eurosafe will market GARD™ animal free tests for skin sensitization to its large client base.
GARD™ is a platform of animal free tests developed by SenzaGen for safety assessment of chemical ingredients and mixtures. The platform offers skin sensitization testing with an accuracy of 94% and the unique possibility to add potency classification according to regulatory requirements. At the same time, GARD™ eliminates the need for laboratory animals, as the tests are performed in test tubes (in vitro).
“This agreement is important for us, as it opens up a very large market being the French cosmetics and pharmaceutical industry. We are very pleased to join efforts with a highly competent and renowned partner such as Eurosafe. Together, we have a clear vision of how GARD™ can contribute to the testing market”, says Anki Malmborg Hager, CEO of SenzaGen.
“The demand from our customers in the cosmetic and pharmaceutical industry for high performing animal free tests is continuously increasing and we strive to offer the best and latest technologies. The GARD™ assay portfolio is unique with its holistic approach and contributes greatly in a modern testing strategy”, says Ashwani Sharma, General Manager of Eurosafe.
For more information, please contact:
Anki Malmborg Hager,
CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822
Ashwani Sharma,
General Manager, Eurosafe
Email: ashwani.sharma@eurosafe.fr
Telephone: + 33 7 85 00 40 56
About GARD™
GARD™ is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability.
This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.
About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com
About Eurosafe
Eurosafe is a French based CRO. Over 30 years Eurosafe has served its customers all around the world for developing cosmetics and pharmaceuticals with 3 kinds of services : in vitro assays, tests on volunteers and regulatory toxicology. Our offering completed now with the GARDskin™ and GARDpotency™ together with our DPRA, H-Clat and Sens-Is assays makes Eurosafe unique in the EU with a complete set of standard and innovative sensitization assays.
This information was submitted for publication, through the contact person set out above on July 16th 2018 at 08:50
SenzaGen AB is listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com
